Stephanie Gill

Dr. Stephanie Gill

orcid

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
8 February 2024 in Obstetrics & Gynecology
Verified
Journal Article
Closed access
SGStephanie Gill
Stephanie Gill
MAMichelle Anderson
Michelle Anderson
JNJoannie Md Neveu
Joannie Md Neveu
BACKGROUND: Hormone therapy (HT) in transgender males requires monitoring. For amenorrheic transmasculine individuals on HT, episodes of abnormal vaginal bleeding should be assessed promptly. CASE: A 33-year-old transgender man on exogenous testosterone therapy for medical gender transition was found to have stage IV endometrioid endometrial adenocarcinoma. Surgical resection was performed for symptom control, and the patient was treated with palliative chemotherapy. The tumor was androgen receptor–negative, and, after a multidisciplinary discussion of the risks and benefits of continuing exogenous testosterone, testosterone therapy was restarted postoperatively. CONCLUSION: Long-term androgen use may have unknown implications for the development of malignancy, and treating reproductive organ cancer in transgender males may be complicated by the desire to continue androgen therapy.

28 July 2025 in International Journal of Gynecological Cancer
Verified
Journal Article
Closed access
SGStephanie Gill
Stephanie Gill
EYElise M. Yates
Elise M. Yates
CBChristian Braun
Christian Braun
KFKyra Fischer
Kyra Fischer
MSMaria Clara Santia
Maria Clara Santia
PRPedro T. Ramirez
Pedro T. Ramirez

18 May 2026 in International Journal of Gynecological Cancer
Verified
Journal Article
Open access
SGStephanie Gill
Stephanie Gill
KCKarlijn Maria Cornelia Cornel
Karlijn Maria Cornelia Cornel
IAIsabella Aversa
Isabella Aversa
BSBrenna Swift
Brenna Swift
ACAllan L. Covens
Allan L. Covens
LGLilian Gien
Lilian Gien
To evaluate the feasibility of sentinel lymph node biopsy in vulvar tumors ≥4 cm and compare groin recurrence rates to tumors <4 cm. This retrospective single-center cohort study included patients with invasive vulvar squamous cell carcinoma between 2008 and 2024. All patients underwent primary surgical excision with planned sentinel lymph node biopsy. Sentinel lymph node procedures in tumors ≥4 cm were performed at the surgeon's discretion. Patients were stratified by tumor size (<4 cm vs ≥4 cm). Analysis included descriptive statistics, Kaplan-Meier curves for groin recurrence-free survival, and multivariate analysis using a Cox proportional hazards model. Among 298 patients (490 groins), 233 had tumors <4 cm and 65 had tumors ≥4 cm. A sentinel lymph node was identified in 93.9% of tumors ≥4 cm. Larger tumors were associated with older age (p = .04), deeper depth of invasion (p < .0001), higher grade (p < .0001), and lymphovascular space invasion (p = .0002). Tumors ≥4 cm had significantly more positive sentinel lymph nodes (p = .04), extracapsular extension (p = .01), and groin node dissections (p = .048). Among 339 groins with negative sentinel lymph node (275 in tumors <4 cm and 64 in tumors ≥4 cm), isolated groin recurrences occurred in 15.6% of larger tumors and 5.1% of smaller tumors (p = .0002). The 3-year groin recurrence-free survival was higher for tumors <4cm (92.5% vs 73.3%, p=.0097). Multivariate analysis revealed that tumor size ≥4 cm was associated with an increased risk of groin recurrence (hazard ratio 1.17, 95% confidence interval 1.05 to 1.29, p = .003). Sentinel lymph node identification in tumors ≥4 cm was feasible but associated with worse groin recurrence-free survival despite negative sentinel lymph nodes. For patients with tumors ≥4 cm, cautious patient selection is important to balance morbidity and prognostic information.

13 April 2024 in Journal of Obstetrics and Gynaecology Canada
Verified
Journal Article
Closed access
SGStephanie Gill
Stephanie Gill
KWKaren Wong
Karen Wong
CCColleen Cook
Colleen Cook

7 April 2025 in Onco
Verified
Journal Article
Open access
PDF file
KHKala Hickey
Kala Hickey
SGStephanie Gill
Stephanie Gill
Zoë BreenZoë Breen
Zoë Breen
KHKaitlyn Harding
Kaitlyn Harding
HYHannah Lauren Victoria Yaremko
Hannah Lauren Victoria Yaremko
Joannie NeveuJoannie Neveu
Joannie Neveu
Peritoneal carcinomatosis is a common presentation found in advanced-stage gastrointestinal (GI) and gynecological cancers. Combined cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) is associated with significant survival benefits for select patients. CRS/HIPEC is not currently provided in Newfoundland and Labrador (NL). The Canadian HIPEC Collaborative Group recommends that centres complete a minimum of one case monthly to maintain competency and achieve good outcomes. Thus, we aimed to demonstrate that the annual patient volume in NL justifies the feasibility of implementing a combined surgical and gynecological oncology CRS/HIPEC program. Methods: A retrospective chart review of the NL Cancer Care Registry identified patients with stage IV colorectal, appendiceal, or gastric cancer and stage III to IV epithelial ovarian cancer over a 1-year period (1 January 2020–31 December 2020) to identify the number of patients meeting the criteria for CRS/HIPEC and/or those referred out of province to receive the treatment. The results are presented as proportions and percentages. Results: Thirty-one patients were eligible to receive CRS/HIPEC during the study period (11 GI, 20 gynecological). Of the GI patients, 63% were referred out of province for the procedure. Gynecological patients underwent CRS and systemic therapy +/− outpatient intraperitoneal chemotherapy in NL. Conclusions: Allowing patients to receive this standard of care treatment near home reduces financial, social, and emotional stressors. Our results confirm a sufficient patient volume to support a combined CRS/HIPEC program in NL. The implementation of this program will require multidisciplinary collaboration, specialized training, equipment, and protocol development.

4 July 2022 in International Journal of Gynecological Cancer
Verified
Journal Article
Closed access
PDF file
SGStephanie Gill
Stephanie Gill
JNJoannie Neveu
Joannie Neveu